Conduit Pharms Stock Price, News & Analysis

CDT Equity (Nasdaq: CDT) approved a 1-for-8 reverse stock split, effective Oct 10, 2025 at 5:00 pm ET, with post-split trading expected on Oct 13, 2025 on Nasdaq under the existing ticker CDT.

As of the Effective Time, every eight pre-split shares will be combined into one share, reducing outstanding common stock to approximately 1,352,448 shares. Par value remains $0.0001. Equity awards, convertible securities, warrants, and plan reserves will be proportionally adjusted. Fractional shares will not be issued; holders entitled to fractions will receive a proportional cash payment. The new CUSIP will be 20678X403. The board said the split is expected to increase the amount of funds the company might be able to raise. VStock Transfer, LLC will act as exchange agent.

CDT Equity (Nasdaq: CDT) has announced its entry into cryptocurrency investment with the purchase of 8.65252366 Bitcoin (BTC) for $1 million, at an average price of $115,285 per BTC. This strategic move marks the company's first step in implementing its cryptocurrency treasury reserve strategy.

The initiative aims to diversify CDT's balance sheet and enhance financial resilience while aligning with growing institutional adoption of digital assets. CFO James Bligh indicated that the company continues to evaluate asset allocation to optimize its treasury portfolio and shareholder returns.

CDT Equity (NASDAQ:CDT) has announced its Board's approval of a cryptocurrency-based treasury reserve strategy to diversify its balance sheet management approach. The company will partner with Sarborg to develop an AI-led system for cryptocurrency market evaluation, featuring real-time analytics and automated execution systems.

The decision follows a strategic review of the cryptocurrency and stablecoin market, including consultations with third-party experts and stakeholders. CDT currently has 3,382,025 shares of common stock outstanding, with 250,000,000 authorized shares. The company continues to fund operations through its ATM facility with A.G.P./Alliance Global Partners while maintaining focus on its Phase-2 ready pharmaceutical pipeline.

CDT Equity (NASDAQ:CDT) has announced a significant breakthrough in its AI-driven drug repurposing strategy. The company, in collaboration with Sarborg, has successfully identified a new biological target and novel therapeutic indication for its lead program AZD1656 through AI-powered disease mapping analysis of over 800 disease signatures.

The company has validated this discovery through successful pre-clinical studies, confirming the AI algorithm's findings. Based on these positive results, CDT plans to initiate additional pre-clinical studies to fully explore the potential of this new therapeutic pathway. The discovery represents a validation of CDT's transition to a lean, disease-agnostic model driven by data-based insights.

Conduit Pharmaceuticals (NASDAQ:CDT) announced its intention to rebrand as CDT Equity Inc., reflecting its evolution into a data-driven biotech development platform. The company leverages artificial intelligence, solid-form chemistry, and asset repositioning to accelerate therapeutic treatment development.

CDT's strategy focuses on unlocking value from clinical-stage compounds with strong Phase I safety data, particularly those deprioritized by larger pharmaceutical companies. Through their Cambridge facility's advanced co-crystallization technologies, they have successfully extended patent life of certain drugs by up to 20 years. The company's pipeline targets inflammatory and autoimmune disorders, male infertility, dermatology, and animal health.

Key partnerships include Sarborg for AI-powered disease mapping and Manoira for animal health market expansion. The company is also evaluating a cryptocurrency treasury reserve strategy.

Conduit Pharmaceuticals (Nasdaq: CDT) has engaged a third-party consultant to evaluate the potential implementation of a partial cryptocurrency treasury reserve strategy. The consultant brings extensive cryptocurrency expertise and has contributed to platforms like CoinDesk.

This initiative aims to explore capital diversification opportunities while maintaining the company's core focus on pharmaceutical development. The move follows Conduit's technology-led approach and recent collaboration with Sarborg, positioning the company at the intersection of pharma, technology, and digital finance.

The company believes a partial cryptocurrency reserve could provide long-term optionality and diversified capital utility, while continuing its focus on AI-driven pharmaceutical development and IP protection in autoimmune and rare diseases.

Conduit Pharmaceuticals (NASDAQ:CDT) has filed four new patent applications for its key assets AZD1656 and AZD5658, including the company's first composition of matter patent for AZD5658. The patents were developed through AI-driven analysis in partnership with Sarborg Limited, focusing on combinations of Conduit's lead assets with existing therapies.

The patent filings represent a significant expansion of Conduit's intellectual property portfolio in autoimmune and inflammatory conditions. The company aims to advance and license these differentiated, IP-rich pharmaceutical assets while maintaining its capital-efficient development model.

Conduit Pharmaceuticals (NASDAQ: CDT) has entered a strategic joint development agreement with Manoira Corporation to evaluate its glucokinase activators AZD1656 and AZD5658 for animal health applications. The collaboration focuses on developing treatments for animal osteoarthritis, with Manoira utilizing its reformulation expertise to generate valuable cross-species insights. The agreement allows Conduit to maintain 100% ownership of intellectual property while gaining access to the $15 billion animal health market. Manoira will fund all development activities in exchange for $500,000 in Conduit stock (154,799 shares at $3.23 per share). The partnership aims to accelerate human clinical programs through cost-efficient preclinical data generation while exploring potential combination therapies with Manoira's patented CBDA co-crystal.

Conduit Pharmaceuticals Inc. (Nasdaq: CDT), a clinical-stage life science company, has received approval from Nasdaq to transfer its common stock listing to the Nasdaq Capital Market. The transfer will be effective at market open on May 23, 2025. This approval follows the Company's confirmation of compliance with Bid Price and Equity Requirements, as previously announced on May 21, 2025.